E. Solsona
Oxford Brookes University · 114 works · 2,451 citations · h-index 23
Top works
- EFFECTIVENESS OF A SINGLE IMMEDIATE MITOMYCIN C INSTILLATION IN PATIENTS WITH LOW RISK SUPERFICIAL BLADDER CANCER: SHORT AND LONG-TERM FOLLOWUP
- THE 3-MONTH CLINICAL RESPONSE TO INTRAVESICAL THERAPY AS A PREDICTIVE FACTOR FOR PROGRESSION IN PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER CANCER
- PROSPECTIVE VALIDATION OF THE ASSOCIATION OF LOCAL TUMOR STAGE AND GRADE AS A PREDICTIVE FACTOR FOR OCCULT LYMPH NODE MICROMETASTASIS IN PATIENTS WITH PENILE CARCINOMA AND CLINICALLY NEGATIVE INGUINAL LYMPH NODES
- Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer
- FEASIBILITY OF TRANSURETHRAL RESECTION FOR MUSCLE INFILTRATING CARCINOMA OF THE BLADDER: LONG-TERM FOLLOWUP OF A PROSPECTIVE STUDY
- Corpus Cavernosum Invasion and Tumor Grade in the Prediction of Lymph Node Condition in Penile Carcinoma
- Feasibility of Transurethral Resection for Muscle-Infiltrating Carcinoma of the Bladder: Prospective Study
- Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): Its impact on management
- Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression.
- Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.
- Conservative Elective Treatment of Upper Urinary Tract Tumors: A Multivariate Analysis of Prognostic Factors For Recurrence and Progression
- Improving the Safety of BCG Immunotherapy by Dose Reduction
- Late Oncological Occurrences Following Radical Cystectomy in Patients with Bladder Cancer
- Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille calmette-guérin with a reduced dose of 27mg in superficial bladder cancer.
- Carcinoma in situ Associated with Superficial Bladder Tumor
- The Prostate Involvement As Prognostic Factor in Patients with Superficial Bladder Tumors
- Extravesical Involvement in Patients with Bladder Carcinoma In Situ: Biological and Therapy Implications
- Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Specimens
- Clinical Panurothelial Disease in Patients with Superficial Bladder Tumors: Therapeutic Implications
- The clinical implications of the Prostate Cancer Prevention Trial